echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Research and development daily BI terminated the development of BI1467335 diabetic retinal lesions

    Research and development daily BI terminated the development of BI1467335 diabetic retinal lesions

    • Last Update: 2020-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2020.09.09 Research and Development NEWS: Side effects of AstraZenecom's new crown vaccine Trials have been suspended; The Phase III clinical phase of Gefapixant in Merca east significantly reduces the frequency of coughing in patients; and the efficacy is comparable to that of intravenous Ertapenan! tebipenem HBr treatment cUTI Phase III clinical success... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
    (click on the title, read the original) "Drug Research and Development" AstraZenecom new crown vaccine side effects trial has been suspended AstraZeneta local time 8, announced that the company will suspend an ongoing vaccine trial due to a disease in a volunteer who participated in the company's new crown vaccine trial developed in collaboration with Oxford University.
    is the first new crown-candidate vaccine to be suspended from Phase III clinical trials.
    Ingham ends BI1467335 clinical development: there is a risk of drug interaction! Grigg Ingeham and Pharmaxis recently jointly announced the termination of the development of BI1467335 to treat moderate to severe non-proliferative diabetic retinal lesions.
    the end of last year, the two sides also announced the end of the development of BI1467335 treatment of non-alcoholic fatty hepatitis.
    Mesa East Gefapixant Phase III Clinically Significantly Reduced Cough Frequency in Patients 8, Mercadon announced that oral selective P2X3 subject antagonist Gefapixant was used to treat refractic or unexplained chronic cough adult patients with the results of two key Phase 3 clinical trials: 24-hour cough frequency decreased statistically in patients who took oral 45 mg Gefapixant twice daily.
    efficacy is comparable to intravenous Erthaman! Tebipenem HBr Treatment cUTI Phase III Clinical Success Recently, Spero Therapeutics announced positive top-line results for evaluating oral antibiotic tebipenem HBr treatment for complex urinary tract infections and acute pyelonephritis in adult patients with critical Stage III ATAPT-PO.
    data showed that oral tebipenem HBr was statistically not as effective as intravenous erthamon.
    Dupixent significantly delayed lung function decline in asthma patients Today, Regeneratives and Sanofi announced that dupilumab, a heavy IL-4/IL-13 inhibitor developed jointly, will maintain efficacy and safety for up to 3 years in open-label Phase 3 clinical expansion trials for patients with moderate to severe asthma and slow down lung function in patients.
    ,
    's first DPP1 inhibitor, has significantly reduced the risk of lung exacerbation, Insmed announced that the final results of the WILLOW study evaluating brensocatib (formerly INS1007) for the treatment of non-cystic fibrosis bronchid dilation (NCFBE) II have been published in the New England Journal of Medicine.
    willow study showed that brensocatib significantly reduced the risk of lung increases in NCFBE patients compared to placebos.
    Drug Approval: Bayer P2X3 antagonists were approved for the first time in China clinical development of treatment of refractic cough CDE latest publicity, Bayer recently declared a new class of 1 drug BAY1817080 was approved in China for the first time clinical, adaptive: treatment of difficult to treat and /or unknown causes of chronic cough.
    Wantay Bio: Nasal influenza virus vector new crown vaccine was clinically approved and started clinical trials 9, Wantay Bio announced that the company and Xiamen University, the University of Hong Kong in cooperation with the development of nasal influenza virus vector new crown pneumonia vaccine recently obtained the National Drug Administration clinical trial application acceptance notice and clinical trial approval, agreed to this product for clinical trials, the batch is valid for 12 months.
    Dsimal pharmaceutical industry for motamine capsules through the consistent evaluation of the 9th, bisceptopharma pharmaceutical industry issued a notice that recently received approval from the State Drug Administration issued on the "tymoamine capsule" (20mg) "drug supplement application approval notice", the company for mothamine capsules (20mg) through generic drug quality and efficacy consistent evaluation.
    Sound Pharmaceuticals" "Ellamod tablets" treatment of primary dryness syndrome clinical application was approved 8 days, synod pharmaceutical industry developed a new anti-rheumic drug Iramod tablets (commodity name: Edsin ®) for the treatment of primary drying syndrome of new drug clinical trial applications were approved.
    and platinum medicine next-generation anti-CTLA-4 antibody was approved for clinical 8 days, and platinum medicine class 1 new drug HBM4003 injection was clinically approved for the treatment of advanced solid tumors.
    Collen Pharmaceuticals", Sidine acid non-mouth collapse tablets" domestic first reported on the 9th, CDE official website shows that Colum Pharmaceuticals submitted the "sour sidana non-mouth collapse tablets of the listing application was undertaken, for the dosage form of the first domestic production.
    4-1BB single anti-QL1806 approved clinical 8, CDE official website shows that Qilu QL1806 injection was approved clinically, intended for the treatment of a variety of malignant tumors.
    Redding Pharmaceutical CD3/CD20 double anti-approved clinical trials in China on the 8th, redding pharmaceutical / regenerative yuan submitted CD3/CD20 dual specific antibody REG1979 injection was approved clinically in China, for the past after systemic treatment recurrence or difficult treatment of B-cell non-Hodgkin lymphoma patients.
    Beihai Kangcheng Ado sulfate enzyme β injection was approved for listing in China on the 9th, Beihai Kangcheng announced that its long-term enzyme replacement therapy drug for the treatment of mucosal polysaccharide storage type II® (Adothionease β injection) has been approved by the State Drug Administration.
    the introduction of "first-in-class" new drugs in China approved clinical CDE latest publicity, and Yu medicine declared a class 1 new drug mavorixafor (X4P-001) in China was approved a clinical implied license, the adaptive disorder is: local late stage or metastasis triple negative breast cancer.
    drug Ming Ju NoriKirensai injection to priority review of the new adaptive disease proposed breakthrough therapy! On the 9th, CDE's official website announced that it intends to include the application for the listing of the drug Ming-Juno CAR-T therapy product "Ricky Lunsai Injection" in the priority review.
    the same time breakthrough therapy column updated, it is proposed to include its second adaptive disease in the breakthrough therapy certification, presumably the adaptive disease is primary resistance pervading large B-cell lymphoma.
    Wanchun Pharmaceutical First In Class new drug Punablin was recognized by the FDA breakthrough therapy 4, Wanchun Pharmaceutical announced that its First-In-Class new drug injection with Punabrin thick solution to obtain the FDA's breakthrough therapy identified as to prevent chemotherapy on non-myelin malignant tumor-induced neutral granulocytosis.
    Research and Development Cooperation: East China Pharmaceuticals and Excientia reached a cooperation through AI to accelerate the development of anti-tumor drugs 9, artificial intelligence drug research and development company Exscientia and East China Pharmaceuticals jointly announced that the two sides have established a partnership to accelerate the discovery of small molecule drugs breakthrough innovative therapies in the field of cancer.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.